In this video interview, Sunir J. Garg, MD, FACS, FASRS, discussed 2-year results of the phase 2 LUNA study on ixoberogene soroparvovec, an intravitreal gene therapy from Adverum Biotechnologies for wet age-related macular degeneration.
The results were presented at the American Society of Retina Specialists annual meeting.
“Everybody received one injection, and it reduced the need for supplemental treatment by 90% over 2 years while maintaining stable visual acuity as well as stable, and really quite good, retinal anatomy,” Garg, chief of the retina service at Wills Eye Hospital and professor